HOME >> BIOLOGY >> NEWS
Pioneering research into health benefits of beauty treatment

Pioneering medical research is going on at the University of Leicester into the use of Botulinum toxin commonly thought of as a beauty treatment for bladder problems.

Dr Douglas Tincello, Senior Lecturer at the Universitys Department of Cancer Studies and Molecular Medicine and Consultant Gynaecologist at the Leicester General Hospital, is carrying out a randomised trial involving injecting botulinum toxin into the bladders of women who have overactive bladder disease.

The trial, which has received a grant of 158,000 from the Moulton Charitable Trust, involves women whose conditions have not improved after tablet treatment.

Overactive bladder is a condition in which the bladder tries to empty itself, rather than the patient retaining control. Symptoms include having to pass water very often day and night, not being able to put off the need to do so, sudden urgency to pass water and sometimes incontinence.

The botulinum toxin relaxes the bladder muscle so it cannot squeeze so hard, and so reduces the need to pass water frequently or suddenly. It may also reduce the sensation of having a full bladder. Dr Douglas Tincello commented:

Overactive bladder is very difficult to treat well. Lots of our patients try different tablets and pelvic floor exercises but at least a third of them will not be better. At the moment the only alternatives are to put up with it, or consider a very big operation which often means the patient ends up with a stoma bag.

Many patients just suffer in silence, but the quality of life when you live with overactive bladder is similar to that of a patient on kidney dialysis.

Botulinum toxin has been tested already in spinal cord injury patients.This study is important to ascertain if it is safe and effective in patients with overactive bladder. Botulinum toxin is a very exciting development and in the future may provide a simple and effective way to improve the quality of life in our patients
'"/>

Contact: Dr. Douglas Tincello
dgt4@le.ac.uk
1-162-588-391
University of Leicester
6-Mar-2007


Page: 1 2

Related biology news :

1. Pioneering research on sleeping sickness wins MERIAL Award for Parasitology
2. Pioneering approach to wastewater treatment earns Stanford engineer the 2007 Stockholm Water Prize
3. Pioneering researcher Dr. Kenneth Lyons Jones receives genetics award from March of Dimes
4. Pioneering ecologist Ruth Patrick honored by Federal-State Commission
5. Pioneering research on ALS muscle disease rewarded
6. Pioneering PET/CT research widens applications of imaging for diabetic foot
7. NIH gives $8M to University of Pittsburgh School of Medicine for myositis research
8. Saudi Arabias KAUST names WHOI first research partner
9. Multinational research: protecting ecology means understanding people, too
10. Newly created cancer stem cells could aid breast cancer research
11. Carnegie Mellons Peter Adams receives EPA research grant

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Pioneering research into health benefits beauty treatment

(Date:7/13/2015)... OXFORD, Conn. , Jul. 13, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/188684 for ... NXT-ID achieves another new convenient and secure method ... expands new, innovative payment methods, introduced with its ...
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... advanced fluid applications and designed for continuous operation up to 1500 bar. The ... ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer is ...
(Date:7/29/2015)... 29, 2015 US-Australian drug discovery company, Novogen ... it is committed to progressing its ground-breaking technology platforms ... and to ensure the Company delivers the best value ... Iain Ross , said the Company currently had an ... programs, discovery programs and academic partnerships and initiatives, and ...
(Date:7/29/2015)... FRANCISCO , July 29, 2015  AsureQuality ... mobile molecular testing for applications in food and ... hand-held, battery powered real-time PCR device, the Freedom4. ... farm right through to the supermarket shelf for ... This includes involvement in animal disease control and ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
Cached News: